Articles
10 June 2009
Vol. 2 No. 14: Immunomodulatory drugs: the foundation for treating hematological malignancies Amsterdam, 15 June 2006
https://doi.org/10.4081/hmr.v2i14.508

Improving treatment outcomes by understanding cytogenetics in myelodysplastic

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
177
Views
336
Downloads

Authors

Aristotle Giagounidis
support@pagepress.org
Myelodysplastic syndromes (MDS) represent a heterogeneous group of blood disorders that are generally characterised by refractory anaemia (RA) or cytopenia, hypercellular bone marrow, and ineffective haematopoiesis. Most cases of MDS have an increased risk of transformation to acute myeloid leukaemia (AML). The prognosis of patients with MDS varies considerably, reflecting the underlying heterogeneity within this class of disorders.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Improving treatment outcomes by understanding cytogenetics in myelodysplastic. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.508